WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/123759    International Application No.:    PCT/GB2012/050584
Publication Date: 20.09.2012 International Filing Date: 16.03.2012
Chapter 2 Demand Filed:    14.01.2013    
A61K 39/35 (2006.01)
Applicants: CAMBRIDGE ENTERPRISE LIMITED [GB/GB]; The Old Schools Trinity Lane Cambridge Cambridgeshire CB2 1TN (GB) (For All Designated States Except US).
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST [GB/GB]; Hills Road Cambridge CB2 0QQ (GB) (For All Designated States Except US).
CLARK, Andrew [GB/GB]; (GB) (For US Only).
EWAN, Pamela [GB/GB]; (GB) (For US Only)
Inventors: CLARK, Andrew; (GB).
EWAN, Pamela; (GB)
Agent: SUTCLIFFE, Nicholas; Mewburn Ellis LLP 33 Gutter Lane London Greater London EC2V 8AS (GB)
Priority Data:
1104537.4 17.03.2011 GB
Abstract: front page image
(EN)The present invention relates to oral immunotherapy for the desensitisation of patients who are hypersensitive to peanut allergen. The immunotherapy comprises increasing the oral dose daily dose of peanut protein administered to the patient at intervals of at least 2 weeks in a series of increments from an initial dose to a maximum dose, the series of dose increments including 2mg, 5mg, 12.5mg, 25mg, 50mg, 0mg, 200mg, 400mg and 800mg; administering a daily oral dose of the maximum dose of peanut protein for at least 2 years and then administering a weekly oral dose of the maximum dose of peanut protein for at least 2 years.
(FR)La présente invention porte sur une immunothérapie orale pour la désensibilisation de patients qui sont hypersensibles à l'allergène arachide. L'immunothérapie consiste à augmenter la posologie quotidienne par dose orale de protéine d'arachide administrée au patient à des intervalles d'au moins 2 semaines dans une série d'incréments allant d'une dose initiale à une dose maximale, la série d'incréments de dose comprenant 2 mg, 5 mg, 12,5 mg, 25 mg, 50 mg, 0 mg, 200 mg, 400 mg et 800 mg; à administrer une dose orale quotidienne de la dose maximale de protéine d'arachide pendant au moins 2 ans, puis à administrer une dose orale hebdomadaire de la dose maximale de protéine d'arachide pendant au moins 2 ans.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)